COMPLEMENTC5 来源于人类血清结构式
|
常用名 | COMPLEMENTC5 来源于人类血清 | 英文名 | C5, HUMAN |
|---|---|---|---|---|
| CAS号 | 80295-53-0 | 分子量 | N/A | |
| 密度 | N/A | 沸点 | N/A | |
| 分子式 | N/A | 熔点 | N/A | |
| MSDS | 美版 | 闪点 | N/A |
| 中文名 | COMPLEMENTC5 来源于人类血清 |
|---|---|
| 英文名 | C5, HUMAN |
| 储存条件 | −70°C |
|---|
| 危害码 (欧洲) | B |
|---|---|
| 危险品运输编码 | NONH for all modes of transport |
| WGK德国 | 3 |
|
Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
N. Engl. J. Med. 350 , 552-559, (2004) Paroxysmal nocturnal hemoglobinuria (PNH) arises from a somatic mutation of the PIG-A gene in a hematopoietic stem cell and the subsequent production of blood cells with a deficiency of surface protei... |
|
|
Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.
Mini Rev. Med. Chem. 11 , 528-535, (2011) Paroxysmal nocturnal hemoglobinuria (PNH) is a hematological disorder characterized by complementmediated hemolytic anemia, thrombophilia and bone marrow failure. The clinical hallmark of PNH is evide... |
|
|
The role of complement inhibition in PNH. Hillmen P.
Hematology Am. Soc. Hematol. Educ. Program 2008(1) , 116-123, (2008)
|
